1. In vitro antifungal activity of voriconazole and fluconazole against Candida spp. isolated from oral fluid Author: Tatarici Andreea Co-authors: Lecturer Dr. Anca Mare Lecturer Dr. Adrian Man Runcan Raul Scientific coordinator: As. Professor Dr. Felicia Toma

2. Background  The incidence of fungal infections is increasing all over the world.  Morbidity caused by invasive candidiasis is increasing worldwide  17% of nosocomial infections in the EU  10% of sepsis in patients hospitalized in the US  Mortality in the EU - up to 50%  Antifungal treatments are often used even as prophylactic treatment, to prevent the development of fungal infections.  This may lead to the selection of resistant strains.

3. Purpose  Evaluation of fluconazole and voriconazole susceptibility of Candida spp. isolated from the oral fluid of adults with dermatological pathology

4. Materials and Methods  A prospective study was conducted between November – December 2014  Fifty samples of oral fluid were collected from adult persons, admitted to the Dermatology Clinic Tg. Mures.  Oral rinsing with 10 ml sterile saline solution, in the morning, before oral hygiene

5. Materials and Methods  The samples were transported to the Department of Microbiology, University of Medicine and Pharmacy Tg. Mures  centrifugated  10 µl from sediment were inoculated on Sabouraud agar

6. Materials and Methods  Incubation  48 hours  37 o C

7. Materials and Methods  The isolated Candida spp. were identified to the level of genus and species by conventional methods of diagnosis  germ tube test  chromogenic culture media

8. Materials and Methods  For each isolate, the susceptibility to voriconazole and fluconazole was assessed  by disk diffusion method  following the CLSI standards - M44- A2

9. Results  Standards CLSI AntifungicDosageResistantIntermediate- susceptible Susceptible Fluconazole25 µg< 14 mm18 – 15 mm> 19 mm Voriconazole1 µg< 13 mm16 - 14 mm> 17 mm

10. Results  Oral fluid colonization with Candida spp. was reported in 86% of the 50 patients included in the study 52.72% 10.9% 5.45% 86% 14%

11. Results  No strains were found resistant to voriconazole.  96.36% of the strains were susceptible to voriconazole  3.63% were intermediate-susceptible  One non-albicans strain (1.81%) was resistant to fluconazole  94.54% were susceptible  3.63% were intermediate-susceptible

12. Discutions  Our study identified a very low percentage of Candida spp. that were resistant to fluconazole and voriconazole  High percentages of resistance to tested azoles (53%) were reported in a local study conducted in the Oral- Maxillofacial Surgery Clinic from Tg. Mures  in this study the samples were collected from hospitalized patients, with specific pathology  Yeast oral colonization in oro-maxillo-facial pathology. Acta Medica Marisiensis. 2014;60(3)

13. Discutions  A recent national study reported low percentages of resistance to fluconazole and voriconazole for Candida albicans species, correlating these data with global and European data  Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study. Eur J Clin Microbiol Infect Dis. 2014 Sep 16.  Our study also identified a low percentages of resistance to fluconazole and voriconazole for Candida spp.

14. Conclusions  Candida albicans was the most frequently isolated Candida species from oral fluid of the patients that were included in this study.  The resistance to azoles that are commonly used for the treatment of candidiasis was recorded in a very small percentage.

15. Bibliography  Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA J Am Med Assoc. 1995 Aug 23;274(8):639–44.  Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care. 2011 Sep 1;1:37.  Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study. Clin Infect Dis. 2004 Aug 1;39(3):309–17.  Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis Off Publ Infect Dis Soc Am. 2003 Nov 1;37(9):1172–7.  Temistocle Despina Luciana, Cecilia Petrovan, Adrian Man. Yeast oral colonization in oro- maxillo-facial pathology. Acta Medica Marisiensis. 2014;60(3)  Minea B1, Nastasa V, Moraru RF, Kolecka A, Flonta MM, Marincu I, Man A, Toma F, Lupse M, Doroftei B, Marangoci N, Pinteala M, Boekhout T, Mares M. Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study. Eur J Clin Microbiol Infect Dis. 2014 Sep 16. [Epub ahead of print]

16. Thank you for your attention!